Patients with KRASG12C mutated-non-small cell lung cancer who were treated with glecirasib, a KRASG12C-inhibitor, experienced promising outcomes according to new findings presented during an April 30 session of the American Society of Clinical Oncology Plenary Series.
Arjan Gower, a hematologist/oncologist at the UCLA Health Jonsson Comprehensive Cancer Center, received a $950,000 grant from the National Comprehensive Cancer Network and Taiho Oncology Inc. to help launch a multi-institutional clinical trial to test zipalertinib, an investigational drug that targets specific EGFR mutations, including Exon 20 insertions, which are known to drive cancer growth and resist standard treatments.
